Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib

Woo, Seung Man; Huh, Chang Hun; Park, Kyung Chan; Youn, Sang Woong

doi:10.1111/j.1346-8138.2007.00369.x

Cited by 30 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Fei et al have demonstrated that Nilotinib suppressed proliferation and function of T-reg cells in a higher concentration in vitro (>10 μM), but not at clinically relevant doses [12]. Aggravation or development of psoriasis during course of Imatinib therapy has been described previously [2][3][4][5][6]. In contrary, Nagayama et al reported a case of improvement in psoriatic lesions during therapy with Imatinib [13].…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Development of Psoriasis Vulgaris in a Chronic Myeloid Leukemia Patient on Second-Generation Tyrosine Kinase Inhibitor Therapy

Thekkudan¹,

Nityan²

2017

J Leuk

View full text Add to dashboard Cite

Development of psoriasis during Imatinib therapy has been described only as few case reports. Psoriasis developing during Nilotinib therapy is also rare, with only two cases reported. In psoriasis, the suppressor activity of T-regulatory cells is decreased, either due to a reduction in the number or due to a reduced ability of T-regulatory cells to produce suppressive cytokines. Imatinib and Nilotinib inhibited the proliferation and immunosuppressive effect of T-regulatory cells in a dose dependent manner. This is the first case report of Dasatinib causing worsening of Psoriasis vulgaris, possibly due to the more potent action of Dasatinib on T regs. Most cases can be managed without any dose reductions in tyrosine kinase inhibitor therapy along with topical therapies and oral methotrexate.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Development of psoriasis during Imatinib therapy has been reported only in a few case reports [2][3][4][5][6]. Nilotinib and Dasatinib are secondgeneration tyrosine kinase inhibitors, approved in patients who have failed or are intolerant to Imatinib and also as first line therapy in CML.…”

Section: Introductionmentioning

confidence: 99%

Development of Psoriasis Vulgaris in a Chronic Myeloid Leukemia Patient on Second-Generation Tyrosine Kinase Inhibitor Therapy

Thekkudan¹,

Nityan²

2017

J Leuk

View full text Add to dashboard Cite

show abstract

“…Adverse reactions induced by imatinib mesylate include hematologic responses and non-hematologic responses, including nausea, vomiting, diarrhea, myalgia, edema, and skin rash1,2. The cutaneous adverse reactions commonly induced by imatinib mesylate (Gleevec™) may be non-specific such as exanthematous rash, pruritus, and edema, or may show eruptions with distinctive clinical characteristics, as in Stevens-Johnson syndrome3, acute generalized exanthematous pustulosis4,5, exfoliative dermatitis6-8, psoriasiform drug eruption or exacerbation of psoriasis9,10, pityriasis rosea -like eruption11,12, and oral lichenoid reaction13,14.…”

Section: Discussionmentioning

confidence: 99%

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Cho

Kim

et al. 2011

Ann Dermatol

View full text Add to dashboard Cite

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.

show abstract

“…It is usually mild-moderate, selflimiting, and easily manageable with antihistamines and/or topical steroids [9]. Exacerbations of psoriasis or psoriasiform eruptions with diffuse erythematosquamous rashes [5,21], and nonfollicular pustular eruptions similar to pustular psoriasis have been observed, developing within a period of 1-7 months after treatment initiation [21]. Erythematous plaques surrounded by desquamative collarette resembling pytiriasis rosea, with histology showing spongiosis, associated with a lymphocytic superficial perivascular infiltrate were described [22,23].…”

Section: Drugs Indications and Mechanisms Of Actionmentioning

confidence: 99%